Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
JCO Oncology Advances · 2026-01 · 3 (1)
DOI: 10.1200/oa-25-00142 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-01. Verfasst von Luigi A De Vitis und 35 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Autor:innen und Institutionen
- Division of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
- Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
- Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
De Vitis, L. A., Larson, M. C., Atkinson, H. J., Block, M. S., Cliby, W. A., Couch, F. J., Dowdy, S. C., Glaser, G. E., Goergen, K. M., Goode, E. L., Gostout, B. S., Hartmann, L. C., Heinzen, E. P., Huang, Y., Jatoi, A., Jones, M., Karow, K. J., Keeney, G. L., Kumar, A., …, & Oberg, A. L. (2026). Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis. JCO Oncology Advances, 3(1). https://doi.org/10.1200/oa-25-00142
Vancouver
De Vitis LA, Larson MC, Atkinson HJ, Block MS, Cliby WA, Couch FJ, et al. Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis. JCO Oncology Advances. 2026;3(1). doi:10.1200/oa-25-00142
BibTeX
@article{DeVitis2026,
author = {De Vitis, Luigi A and Larson, Melissa C and Atkinson, Hunter J and Block, Matthew S and Cliby, William A and Couch, Fergus J and Dowdy, Sean C and Glaser, Gretchen E and Goergen, Krista M and Goode, Ellen L and Gostout, Bobbie S and Hartmann, Lynn C and Heinzen, Ethan P and Huang, Yajue and Jatoi, Aminah and Jones, Monica and Karow, Katie J and Keeney, Gary L and Kumar, Amanika and Langstraat, Carrie L and Lee, Sun-Hee and Mariani, Andrea and Ostby, Stuart A and Peethambaram, Prema P and Podratz, Karl C and Shahi, Maryam and Sherman, Mark E and Sommerfield, Marla Kay and Swisher, Elizabeth M and Wall, Vonda M and Weroha, S John and Wahner Hendrickson, Andrea E and Maurer, Matthew J and Kaufmann, Scott H and Bakkum-Gamez, Jamie N and Oberg, Ann L},
title = {Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {1},
doi = {10.1200/oa-25-00142}
}
EUVIMED